Enteral administration of alanyl-[2-15N]glutamine contributes more to the de novo synthesis of arginine than does intravenous infusion of the dipeptide in humans

19Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: We previously confirmed in humans the existence of a pathway of glutamine into citrulline and arginine, which is preferentially stimulated by luminally provided glutamine. However, because glutamine is unstable, we tested this pathway with a stable dipeptide of glutamine. Objectives: The objectives were to explore whether alanyl-glutamine contributes to the synthesis of arginine in humans and whether this depends on the route of administration. Design: The study was conducted under postabsorptive conditions during surgery. Sixteen patients received alanyl-[2-15N]glutamine enterally or intravenously together with intravenously administered stable-isotope tracers of citrulline and arginine. Blood was collected from an artery, the portal vein, a hepatic vein, and the right renal vein. Arterial and venous enrichments and (tracer) net balances of alanyl-glutamine and glutamine, citrulline, and arginine across the portal-drained viscera, liver, and kidneys were determined. Parametric tests were used to test results (mean ± SEM). P < 0.05 was considered significant. Results: Twice as much exogenous glutamine was used for the synthesis of citrulline when alanyl-glutamine was provided enterally (5.9 ± 0.6%) than when provided intravenously (2.8 ± 0.3%) (P < 0.01). Consequently, twice as much exogenous glutamine was used for the synthesis of arginine when alanyl-glutamine was provided enterally (5 ± 0.7%) than when provided intravenously (2.4 ± 0.2%) (P < 0.01). However, results at the organ level did not explain the differences due to route of administration. Conclusions: Alanyl-glutamine contributes to the de novo synthesis of arginine, especially when provided enterally. A stable-isotope study using a therapeutic dose of alanyl-glutamine is needed to investigate the clinical implications of this finding. © 2009 American Society for Nutrition.

Cite

CITATION STYLE

APA

Ligthart-Melis, G. C., Van De Poll, M. C. G., Vermeulen, M. A. R., Boelens, P. G., Van Den Tol, M. P., Van Schaik, C., … Van Leeuwen, P. A. M. (2009). Enteral administration of alanyl-[2-15N]glutamine contributes more to the de novo synthesis of arginine than does intravenous infusion of the dipeptide in humans. American Journal of Clinical Nutrition, 90(1), 95–105. https://doi.org/10.3945/ajcn.2008.26399

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free